Survodutide’s Number, Foundayo’s Bias
Week Of April 25 – May 1, 2026
Boehringer’s survodutide read out in Phase 3, the first GLP-1/glucagon dual agonist to do so. The 16.6% weight loss at 76 weeks lands above semaglutide but below tirzepatide. This establishes a benchmark for the rest of the dual class still in mid-stage development. The Trial Spotlight goes into where survodutide fits, and whether the results may point toward a greater focus on liver disease (MASH) for this drug. The Mechanism Explained looks at biased agonism, a phrase that gets used everywhere in oral GLP-1 marketing without much explanation. With Foundayo just launched, I discuss what makes orforglipron’s “partial + biased” design different from MET-097’s “fully biased” peptide.
Some interesting things I was reading this week highlight the wide range of the GLP-1 story: a new Lancet trial of semaglutide in patients with alcohol use disorder and obesity suggests the class may have meaningful effects beyond weight and glycemic control, while this NEJM perspective on GLP-1 receptor agonists and eating disorders (paywalled) focuses on a risk area that may draw more scrutiny as use expands. I also found this Scientific American piece on the anti-inflammatory effects of GLP-1 drugs decent as a broader framing for why the category continues to generate interest well beyond obesity treatment.
I’ve also opened up a Weekly Updates tab on the dashboard for readers who prefer a more structured view of the week’s trial changes and results without the editorial framing or educational sections I add here. It surfaces the week’s trial changes and results, with a look at the kind of drill-down details available in the full dashboard.
🔥 THIS WEEK’S KEY DEVELOPMENTS
Survodutide achieves 16.6% weight loss in Phase 3 SYNCHRONIZE-1
Boehringer Ingelheim and Zealand Pharma announced that survodutide, an unimolecular GLP-1/glucagon receptor dual agonist, met co-primary endpoints in the Phase 3 SYNCHRONIZE-1 trial in adults with obesity or overweight without type 2 diabetes. Participants achieved a statistically significant average weight loss of 16.6% (17.8 kg) at 76 weeks compared to 3.2% for placebo, with 85.1% reaching at least 5% weight reduction (vs 38.8% for placebo). The trial also met its key secondary endpoint for waist circumference reduction. Safety findings showed mild-to-moderate gastrointestinal events consistent with the GLP-1 class. Full data are scheduled for the American Diabetes Association’s 2026 Scientific Sessions. This is the first Phase 3 readout for any GLP-1/glucagon dual agonist (see Trial Spotlight below for context across the class).
Press | Trial: NCT06066515 | Mechanism: GLP-1/glucagon dual agonist
📰 PRESS
FDA proposes excluding semaglutide, tirzepatide, and liraglutide from 503B bulks list
Press | Mechanism: incretin receptor agonists (GLP-1 and GLP-1/GIP)
Zealand and Roche announce plans to advance petrelintide into Phase 3 for chronic weight management (no Phase 3 trials registered yet)
Press | Mechanism: amylin analog
Lilly Q1 2026: revenue +56%, raised full-year guidance, Foundayo (orforglipron) approved and launched in the US
Press | Mechanism: oral GLP-1 (orforglipron)
Novo Nordisk to present 52 abstracts at ECO 2026, including STEP UP, OASIS 4, and REDEFINE 1 post hoc analyses
Press | Mechanism: GLP-1 receptor agonist (Wegovy, oral semaglutide); GLP-1 + amylin combination (CagriSema)
Amgen positions MariTide as potential “best monthly” obesity drug at Q1 2026
Press | Mechanism: GLP-1 agonist + GIP antagonist (antibody-peptide conjugate)
Canada approves first generic semaglutide (Dr. Reddy’s), a “test case for the world”
Press | Mechanism: GLP-1 receptor agonist
💡 TRIAL SPOTLIGHT
Educational spotlight selected by editors
Survodutide Reads Out: 16.6% Sets a Phase 3 Floor for GLP-1/Glucagon Dual Agonists
Boehringer Ingelheim and Zealand Pharma have unveiled the first Phase 3 results for a GLP-1/glucagon dual receptor agonist, setting a new benchmark in the evolving obesity treatment landscape. In the SYNCHRONIZE-1 trial, which enrolled adults with overweight or obesity but not type 2 diabetes, survodutide demonstrated a placebo-adjusted mean weight loss of 16.6% after 76 weeks of treatment. This unimolecular dual agonist combines the appetite-suppressing effects of GLP-1 with the potential metabolic benefits of glucagon, which is thought to increase energy expenditure and fat metabolism in the liver. The result positions survodutide’s efficacy above the GLP-1 monotherapy semaglutide (~15%) but below the dual GLP-1/GIP agonist tirzepatide (~21%), suggesting the addition of glucagon offers a meaningful but not class-leading boost in weight reduction.
The SYNCHRONIZE-1 readout provides a crucial, if mixed, signal for the broader class of GLP-1/glucagon agonists in development, which includes Innovent’s China-approved mazdutide, Altimmune’s pemvidutide, Merck’s efinopegdutide, and AstraZeneca’s AZD9550 (now in the ASCEND combo trial). While the 16.6% weight loss is a strong result likely sufficient for regulatory approval, it tempers expectations that glucagon co-agonism would dramatically outperform existing dual-incretin therapies. The strategic focus for survodutide may now sharpen around its potential as a treatment for metabolic dysfunction-associated steatohepatitis (MASH), a severe form of fatty liver disease. Survodutide has already received a Breakthrough Therapy Designation from the FDA for MASH, and its liver-targeted mechanism could carve out a significant niche, even if its obesity data doesn’t top the charts. The full picture will become clearer when detailed data, including discontinuation rates, are presented at a future medical congress, which will help clarify the therapy’s overall tolerability.
ClinicalTrials.gov: NCT06066515 (SYNCHRONIZE-1) | NCT06066528 (SYNCHRONIZE-2, T2D) | NCT06077864 (SYNCHRONIZE-CVOT) | Boehringer press release
🔬 MECHANISM EXPLAINED
Understanding the science behind the therapeutics
What “Biased Agonism” Actually Means: Inside Orforglipron, MET-097, and Aleniglipron’s Molecular Designs (Example drugs: Orforglipron, MET-097, Aleniglipron)
The recent launch of Eli Lilly’s Foundayo (orforglipron) puts a clinical spotlight back on biased agonism, a receptor design strategy reshaping the incretin landscape. The GLP-1 receptor is a class B G-protein-coupled receptor that signals through two distinct pathways: G-protein activation, which drives cAMP production and satiety, and beta-arrestin recruitment, which scaffolds the receptor for internalization, desensitization, and degradation. Balanced agonists like semaglutide activate both pathways, meaning that acute beta-arrestin signaling in vagal afferents can trigger dose-limiting nausea before the receptor is pulled inside the cell. Biased agonists preferentially trigger the G-protein pathway, keeping the receptor on the cell surface longer while minimizing nausea-inducing beta-arrestin spikes. Orforglipron applies a unique twist to this concept as a non-peptide small molecule that is both G-protein biased and a partial agonist. While fully biased full agonists rely entirely on skewed pathway ratios to widen the therapeutic window, orforglipron’s partial agonism naturally caps peak signaling even at receptor saturation, compounding the tolerability benefits of its bias and allowing Lilly to push oral dosing high enough to achieve the 12.4% weight loss seen in the ATTAIN-1 trial.
This molecular strategy is particularly vital for oral drugs, which require massive doses to overcome low bioavailability. However, the “biased” label is applied loosely across press releases, with companies relying on wildly varying cAMP-to-arrestin ratios and cell-based assays to make their claims. Structure Therapeutics engineered its oral small molecule aleniglipron (GSBR-1290) for a more extreme bias than orforglipron, claiming zero measurable beta-arrestin recruitment alongside a 16.3% placebo-adjusted weight loss in its Phase 2 ACCESS-II study. Pfizer is applying this concept to injectables with MET-097, a fully biased peptide layering ultra-long-acting pharmacokinetics over reduced beta-arrestin signaling as it initiates the Phase 3 VESPER-4 trial. Even tirzepatide exhibits inherent G-protein bias at the GLP-1 receptor, a molecular quirk published in 2020 that partially explains its superior tolerability profile. As we explored last November with the oral peptide ecnoglutide, which just registered a new Phase 2 weight maintenance trial (NCT07553299), manipulating these signaling pathways is a global development trend. While early clinical data show impressively low discontinuation rates, head-to-head clinical experience against standard incretins will ultimately reveal whether these varied biased and partial-agonist designs translate into distinct real-world advantages.
ClinicalTrials.gov: NCT05869903 (ATTAIN-1, orforglipron) | NCT06703021 (ACCESS-II, aleniglipron) | NCT07311850 (VESPER-4, MET-097) | NCT07553299 (Ecnoglutide weight maintenance)
🆕 NEWLY REGISTERED TRIALS (9 in last week)
HRS9531 Phase 3 evaluating efficacy and safety in participants with atherosclerotic cardiovascular disease (Fujian Shengdi Pharmaceutical / Hengrui; licensed ex-China to Kailera as KAI-9531, n=9,262)
[New Indications]
Trials: NCT07551492 | Mechanism: Dual GLP-1/GIP agonist
Cagrilintide Phase 1 investigating the influence on food intake and appetite in individuals with overweight or obesity (Novo Nordisk, n=120)
[Weight Loss/Efficacy]
Trials: NCT07557953 | Mechanism: Dual amylin/calcitonin receptor agonist
HRS9531 Phase 1 evaluating safety, tolerability, and pharmacokinetics in adolescents with obesity (Fujian Shengdi Pharmaceutical, n=48)
[Weight Loss/Efficacy | Safety/Tolerability]
Trials: NCT07559136 | Mechanism: Dual GLP-1/GIP agonist
Tirzepatide Phase 1 evaluating dopaminergic effects and reward processing in individuals with Alcohol Use Disorder (NIAAA, n=176)
[New Indications]
Trials: NCT07559500 | Mechanism: Dual GLP-1/GIP agonist
SRSD384 Phase 1 evaluating the safety, tolerability, and pharmacokinetics of this novel agent in overweight or obese participants (Sirius Therapeutics, n=78)
[Safety/Tolerability]
Trials: NCT07557355 | Mechanism: Other metabolic mechanism
AIM-MAINTAIN Phase 4 comparing AI-assisted multi-domain lifestyle intervention versus tirzepatide for weight loss maintenance in adults with type 2 diabetes (Huazhong University of Science and Technology, n=400)
[Weight Loss/Efficacy]
Trials: NCT07555730 | Mechanism: Dual GLP-1/GIP agonist
Ecnoglutide (VRB-101) Phase 2 evaluating a weekly oral dose for weight maintenance in adults with obesity or overweight and weight-related comorbidities (Verdiva, n=120)
[Weight Loss/Efficacy | Oral Formulations]
Trials: NCT07553299 | Mechanism: Biased GLP-1 receptor agonist
Incretin Therapies Phase 4 investigating the clinical impact of incretin-based treatments on patients with obesity-related heart failure with preserved ejection fraction (Columbia University, n=50)
[New Indications]
Trials: NCT07554638 | Mechanism: Dual GLP-1/GIP agonist
Combatting Muscle Loss in Obese Adult Patients on GLP-1 Medications Phase 4 evaluating if a 12-week exercise and nutrition program can mitigate muscle and bone loss during GLP-1 treatment (William Marsh Rice University, n=20)
[Weight Loss/Efficacy]
Trials: NCT07554417 | Mechanism: GLP-1 receptor agonist
This newsletter compiles publicly available information from press releases, news sources, and trial registries. Not investment advice.
Get in touch: Reply to this email, leave a comment on the post, or find me on X @GLP1observer. Explore the GLP-1 dashboard at glp1.bio1up.com or at glp1.bio1up.com/weekly-updates for a structured view of weekly updates and the ability to drill down on details.